Gram-negative bacterial infections: Research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group

Clinical Infectious Diseases

Volumn 64, Issue , 2017, Pages S30-S35

  Doi, Yohei ^a   Bonomo, Robert A ^b   Hooper, David C ^c   Kaye, Keith S ^d   Johnson, James R ^e   Clancy, Cornelius J ^a   Thaden, Joshua T ^f   Stryjewski, Martin E ^g   Van Duin, David ^h  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e Urology Section   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CEMIC   (Argentina)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial resistance; Clinical trials; Gram negative; Interventional studies; Observational studies

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; MINOCYCLINE; PLAZOMICIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ARTICLE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CRITICALLY ILL PATIENT; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; PRIORITY JOURNAL; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; RESEARCH PRIORITY; TREATMENT OUTCOME; URINARY TRACT INFECTION; ANTIBIOTIC RESISTANCE; CLINICAL STUDY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; LEADERSHIP; MICROBIOLOGY; ORGANIZATION AND MANAGEMENT; RESEARCH; TRENDS;

ANTI-BACTERIAL AGENTS; CLINICAL STUDIES AS TOPIC; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LEADERSHIP; RESEARCH;

EID: 85026371092     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw829     Document Type: Article

References (25)

1. World Health Organization. Antimicrobial resistance-global report on surveillance. 2014. Available at: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748-eng.pdf. Accessed 3 July 2016.
2. Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Available at: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20 for%20the%20health%20and%20wealth%20of%20nations-1.pdf. Accessed 3 July 2016.
3. Flamm RK, Sader HS, Farrell DJ, Jones RN. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis 2014;80:233-8.
4. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53:60-7.
5. van Duin D, Perez F, Rudin SD, et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother 2014;58:4035-41.
6. Hauck C, Cober E, Richter SS, et al; Antibacterial Resistance Leadership Group. Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections. Clin Microbiol Infect 2016;22:513-9.
7. Messina JA, Cober E, Richter SS, et al; Antibacterial Resistance Leadership Group. Hospital readmissions in patients with carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2016;37:281-8.
8. van Duin D, Cober ED, Richter SS, et al. Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin Microbiol Infect 2014;20:O1117-20.
9. van Duin D, Cober E, Richter SS, et al. Residence in skilled nursing facilities is associated with tigecycline nonsusceptibility in carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2015;36:942-8.
10. van Duin D, Cober E, Richter SS, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2015;70:1203-11.
11. Wright MS, Perez F, Brinkac L, et al. Population structure of KPC-producing Klebsiella pneumoniae isolates from midwestern U. S. hospitals. Antimicrob Agents Chemother 2014;58:4961-5.
12. Tamma PD, Han JH, Rock C, et al; Antibacterial Resistance Leadership Group. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis 2015;60:1319-25.
13. Goodman KE, Lessler J, Cosgrove SE, et al; Antibacterial Resistance Leadership Group. A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum β-lactamase-producing organism. Clin Infect Dis 2016;63:896-903.
14. Evans SR, Hujer AM, Jiang H, et al; Antibacterial Resistance Leadership Group. Rapid molecular diagnostics, antibiotic treatment decisions, and developing approaches to inform empiric therapy: PRIMERS I and II. Clin Infect Dis 2016;62:181-9.
15. Evans SR, Hujer AM, Jiang H, et al. Informing antibiotic treatment decisions: evaluating rapid molecular diagnostics (RMDs) to identify susceptibility and resistance to carbapenems against Acinetobacter spp. PRIMERS III. J Clin Microbiol 2016. doi:10.1128/JCM.01524-16.
16. Kazmierczak KM, Biedenbach DJ, Hackel M, et al. Global dissemination of blaKPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother 2016;60:4490-500.
17. Neuner EA, Yeh JY, Hall GS, et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 2011;69:357-62.
18. Manca C, Hill C, Hujer AM, et al. Leading antibacterial laboratory research by integrating conventional and innovative approaches: the Laboratory Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S13-7.
19. Huvane J, Komarow L, Hill C, et al. Fundamentals and catalytic innovation: the Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S18-23.
20. Cross HR, Harris A, Arias RM, et al. Transforming concepts into clinical t rials and creating a multisite network: the Leadership and Operations Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S8-12.
21. Clancy CJ, Chen L, Shields RK, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 2013;13:2619-33.
22. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20.
23. Sastry S, Doi Y. Fosfomycin: resurgence of an old companion. J Infect Chemother 2016;22:273-80.
24. Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 2015;36:85-98.
25. Landman D, Babu E, Shah N, et al. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J Antimicrob Chemother 2010;65:2123-7.